Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech

Aubagne, January 7, 2025

Half-year liquidity contract statement for Sartorius Stedim Biotech

Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31, 2024:
 

• 29,563 shares
• € 6,232,769.05
• Number of executions on buy side on semester: 5,450
• Number of executions on sell side on semester: 5,333
• Traded volume on buy side on semester: 281,035 shares for € 49,893,952.42
• Traded volume on sell side on semester: 297,764 shares for € 53,521,926.85

As a reminder :
 

The following resources appeared on the last half year statement on June 30, 2024 on the liquidity account:
 

• 46,292 shares
• € 2,521,189.91
• Number of executions on buy side on semester: 6,493
• Number of executions on sell side on semester: 5,322
• Traded volume on buy side on semester: 305,402 shares for €  69,412,550.00
• Traded volume on sell side on semester: 273,281 shares for €  63,664,027.43

The following resources appeared on the liquidity account when the activity started:

• 0 shares
• € 10,000,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros. Currently, more than 10,600 employees are working for customers around the globe.

Contact

Petra Müller

Head of Investor Relations

+49 (0)551.308.6035

Petra.mueller2@sartorius.com

Sartorius Stedim Biotech S.A.

Z.I. Les Paluds

Avenue de Jouques, CS 91051

13781 Aubagne Cedex, France

Phone: +33.(0)4.42.84.56.00

Fax: +33.(0)4.42.84.56.19

www.sartorius.com